Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Benchtop Mass Spectrometers

By Drug Discovery Trends Editor | May 25, 2010

Waters Corporation introduced two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).

The Xevo TQ-S and Xevo G2 QTof are the newest members of the Xevo family of benchtop mass spectrometers first introduced in 2008 and are the most powerful mass spectrometers in their class. Combined with Waters ACQUITY UltraPerformance LC (UPLC) Systems these mass spectrometers offer scientists an unequalled combination of separations power with highest levels of sensitivity whether for compound identification, quantification, and screening, or for extracting the most information from the smallest sample volumes all in a single analysis.

Said Brian Smith, V.P. Mass Spectrometry Operations, Waters Division, “With today’s announcements, Waters has firmly established its leadership position in high-performance mass spectrometry. The new features and innovations scientists will find in our new Xevo mass spectrometers, more than anything else, are intended to deliver results. As they have told us time and again, that’s what really counts.”

At a press conference, Waters global Vice President of Worldwide Marketing, Dr. Rohit Khanna, remarked, “Our customers have told us they want high-quality, high-impact results faster, and with less effort. These new additions to our Xevo family of mass spectrometers mean we can deliver applications-specific UPLC/MS/MS systems that can help them achieve their scientific and business objectives and put answers to complex challenges within easy reach.”

Waters expects to begin shipping the Xevo G2 QTof system in June and the Xevo TQ-S system in September.

Waters Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50